Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis.

Multicancer early-detection blood tests did not significantly reduce stage III or IV cancer incidence after three screening rounds in a large trial of over 142,000 participants.

• Why it matters: Early detection of advanced cancers can improve outcomes, but the clinical utility of blood-based multicancer screening remains uncertain, necessitating rigorous evaluation to inform screening guidelines.
• What they did: A randomized controlled trial involving 71,122 participants in England compared blood-based multicancer screening plus usual care to usual care alone, measuring cancer stage at diagnosis over three screening rounds.
• The result: The study found no significant difference in the incidence of late-stage cancers between groups, though a modest reduction in stage IV cancers was observed, indicating further follow-up is needed to assess long-term benefits.